Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?

Authors

  • Joel R. Rosh MD,

    Corresponding author
    1. Goryeb Children's Hospital/Atlantic Health, Morristown, New Jersey
    • Pediatric Gastroenterology, Goryeb Children's Hospital/Atlantic Health, 100 Madison Avenue, Morristown, NJ 07962
    Search for more papers by this author
    • Drs. Griffiths, Gross, Hyams, and Rosh have served as consultants for Centocor. Dr. Hyams has received research support from Centocor and has served as a consultant for Abbott Labs. Dr. Rosh has served as a speaker for Abbott Labs.

  • Thomas Gross MD,

    1. Columbus Children's Hospital, Columbus, Ohio
    Search for more papers by this author
    • Drs. Griffiths, Gross, Hyams, and Rosh have served as consultants for Centocor. Dr. Hyams has received research support from Centocor and has served as a consultant for Abbott Labs. Dr. Rosh has served as a speaker for Abbott Labs.

  • Petar Mamula MD,

    1. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Anne Griffiths MD,

    1. Toronto Sick Children's, Toronto, Canada
    Search for more papers by this author
    • Drs. Griffiths, Gross, Hyams, and Rosh have served as consultants for Centocor. Dr. Hyams has received research support from Centocor and has served as a consultant for Abbott Labs. Dr. Rosh has served as a speaker for Abbott Labs.

  • Jeffrey Hyams MD

    1. Connecticut Children's Medical Center, Hartford, Connecticut
    Search for more papers by this author
    • Drs. Griffiths, Gross, Hyams, and Rosh have served as consultants for Centocor. Dr. Hyams has received research support from Centocor and has served as a consultant for Abbott Labs. Dr. Rosh has served as a speaker for Abbott Labs.


Abstract

Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)—a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

Ancillary